Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Cited by (1,051)

Items 601–700 of 1,051

1. Comprehensive T cell repertoire characterization of non-small cell lung cancer
   Reuben, Alexandre, Zhang, Jiexin, Chiou, Shin-Heng, Gittelman, Rachel M., Li, Jun, Lee, Won-Chul, Fujimoto, Junya, Behrens, Carmen, Liu, Xiaoke, Wang, Feng et al. · 2020 · Nature Communications
2. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
   Stefanie N. Linch, Michael J. McNamara, William L. Redmond · 2015 · Frontiers in Oncology
3. Immune checkpoint blockade in hematologic malignancies
   Philippe A. Armand · 2015 · Blood
4. Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction
   Christian Alexander Bauer, Edward Y. Kim, Francesco Marangoni, Esteban Carrizosa, Natalie Claudio, Thorsten R. Mempel · 2014 · Journal of Clinical Investigation
5. Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer
   Valsamo Anagnostou, Julie Renee Brahmer · 2015 · Clinical Cancer Research
6. PD-L1 expression in small cell neuroendocrine carcinomas
   Anne Maria Schultheis, Andreas Hans Scheel, Luka Ozretić, Julie George, Roman Kurt Thomas, Thorsten Hagemann, Thomas Zander, Jürgen Wolf, Reinhard Buettner · 2015 · European Journal of Cancer
7. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents
   Matteo Santoni, Emanuela Romagnoli, Tiziana Saladino, Laura Foghini, Stefania Guarino, Marco Capponi, Massimo Giannini, Paolo Decembrini Cognigni, Gerardo Ferrara, Nicola Battelli · 2017 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
8. Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
   Moslehi, Javid, Lichtman, Andrew H., Sharpe, Arlene H., Galluzzi, Lorenzo, Kitsis, Richard N. · 2021 · Journal of Clinical Investigation
9. Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
   Samuel A. Kerk, Thales Y. Papagiannakopoulos, Yatrik Madhukar Shah, Costas Andreas Lyssiotis · 2021 · Nature reviews. Cancer
10. B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
    Aaron Scott Mansfield, Anja Christiane Roden, Tobias Peikert, Yuri M. Sheinin, Susan M. Harrington, Christopher J. Krco, Haidong Dong, Eugene D. Kwon · 2014 · Journal of Thoracic Oncology
11. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
    Majidpoor, Jamal, Mortezaee, Keywan · 2021 · Clinical Immunology
12. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy
    Lines, J. Louise, Sempere, Lorenzo F., Broughton, Thomas, Wang, Li, Noelle, Randolph · 2014 · Cancer Immunology Research
13. Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
    Ahmad A. Tarhini · 2013 · Scientifica
14. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
    Heidrun Gevensleben, Dimo Dietrich, Carsten Golletz, Susanne Steiner, Maria Jung, Thore Thiesler, Michael Majores, Johannes Stein, Barbara Uhl, Stefan Müller et al. · 2015 · Clinical Cancer Research
15. Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer
    David Balli, Andrew J. Rech, Ben Z. Stanger, Robert H. Vonderheide · 2016 · Clinical Cancer Research
16. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
    Kazuhiro Koikawa, Shin Kibe, Futoshi Suizu, Nobufumi Sekino, Nami Kim, Theresa D. Manz, Benika J. Pinch, Dipikaa Akshinthala, Ana Verma, Giorgio Gaglia et al. · 2021 · Cell
17. Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies
    Sandra Heskamp, Willemijn A. Hobo, Janneke D.M. Molkenboer‐Kuenen, Daniel Olive, Wim J.G. Oyen, Harry Dolstra, Otto C. Boerman · 2015 · Cancer Research
18. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
    Hyun Tae Lee, Sang Hyung Lee, Yong‐Seok Heo · 2019 · Molecules
19. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy
    Shuo Yang, Wei Wei, Qi Zhao · 2020 · International Journal of Biological Sciences
20. Programmed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus
    Katrien Clotman, Katleen Janssens, Pol M. Specenier, Ilse Weets, Christophe E.M. De Block · 2018 · The Journal of Clinical Endocrinology & Metabolism
21. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
    Jonathan L. Curry, Michael T. Tetzlaff, Priyadharsini Nagarajan, Carol R. Drucker, Adi K. Diab, Sharon R. Hymes, Madeleine A. Duvic, Wen‐Jen Hwu, Jennifer Ann Wargo, Carlos Antonio Torres-Cabala et al. · 2016 · Journal of Cutaneous Pathology
22. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
    Lars Henning Schmidt, Andreas Kümmel, Dennis Görlich, Michael Möhr, Sebastian Bröckling, Jan Henrik Mikesch, Inga Grünewald, Alessandro Marra, Anne Maria Schultheis, Eva Wardelmann et al. · 2015 · PLoS ONE
23. High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma
    Yueh-Min Lin, Wen‐Wei Sung, Ming‐Ju Hsieh, Shih-Chen Tsai, Hung‐Wen Lai, Shu-Mei Yang, Ko-Hong Shen, Mu-Kuan Chen, Huei Lee, Kun-Tu Yeh et al. · 2015 · PLoS ONE
24. Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome
    Rhiannon Beckers, Christina I. Selinger, Ricardo E. Vilain, Jason Madore, James S. Wilmott, Kate Harvey, Anne Holliday, Caroline Louise Cooper, Elizabeth Robbins, David J. Gillett et al. · 2015 · Histopathology
25. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
    Chunwan Lu, Priscilla S. Redd, Jeffrey R. Lee, Natasha M. Savage, Kebin Liu · 2016 · OncoImmunology
26. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
    Jiaqiao Fan, Mengfei Wang, Hailong Chen, Dong Shang, Jugal Kishore Das, Jianxun Jim Song · 2020 · Molecular Cancer
27. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
    Ruonan Zhang, Yajing Yang, Wenjing Dong, Mingen Lin, Jing He, Xinchao Zhang, Tongguan Tian, Yunlong Yang, Kun Chen, Qun‐Ying Lei et al. · 2022 · Proceedings of the National Academy of Sciences
28. A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
    David Gardiner, Jacob Paul Lalezari, Eric Lawitz, Michael DiMicco, Rheem Ghalib, K. Rajender Reddy, Kyong‐Mi Chang, Mark Sulkowski, Steven O’ Marro, Jeffrey Anderson et al. · 2013 · PLoS ONE
29. Prognostic significance of PD-L1 and PD-L2 in breast cancer
    Mauricio Z. Baptista, Luı́s Otávio Sarian, Sophie Derchain, Glauce Aparecida Pinto, José Vassallo · 2015 · Human Pathology
30. Targeting immune cells for cancer therapy
    Sin Yee Gun, Sharon Wei Ling Lee, Je Lin Sieow, Siew Cheng Wong · 2019 · Redox Biology
31. The cancer antigenome
    Bianca Heemskerk, Pia Kvistborg, Ton N. Schumacher · 2012 · The EMBO Journal
32. Nivolumab in NSCLC: latest evidence and clinical potential
    Raghav Sundar, Byoung Chul Cho, Julie Renee Brahmer, Ross Andrew Soo · 2015 · Therapeutic Advances in Medical Oncology
33. Novel technologies and emerging biomarkers for personalized cancer immunotherapy
    Jianda D. Yuan, Priti S. Hegde, Raphael Clynes, Periklis G. Foukas, Alexandre Harari, Thomas O. Kleen, Pia Kvistborg, Cristina Maccalli, Holden Terry Maecker, David B. Page et al. · 2016 · Journal for ImmunoTherapy of Cancer
34. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
    Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus Otho Butler, Mary Lenora Disis, Jérôme Galon, Leif Håkansson, Brent Allen Hanks, Vaios Karanikas, Samir N. Khleif et al. · 2017 · Journal for ImmunoTherapy of Cancer
35. Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer
    Yongwoo David Seo, Xiuyun Jiang, Kevin M. Sullivan, Florencia G. Jalikis, Kimberly S. Smythe, Arezou Abbasi, Marissa Vignali, James Oh Park, Sara K. Daniel, Seth M. Pollack et al. · 2019 · Clinical Cancer Research
36. Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy
    Qiang Zhang, Michael D. Green, Xueting Lang, Jenny Lazarus, Joshua D. Parsels, Shuang Wei, Leslie A. Parsels, Jiaqi Shi, Nithya Ramnath, Daniel Richard Wahl et al. · 2019 · Cancer Research
37. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012
    Claus Garbe, Ketty Peris, Axel Hauschild, Philippe Saïag, Mark Ross Middleton, Alan Spatz, Jean‐Jacques Grob, Josep Malvehy, Julia Newton‐Bishop, Alexander Stratigos et al. · 2012 · European Journal of Cancer
38. Human Tumor Antigens and Cancer Immunotherapy
    Nathalie Vigneron · 2015 · BioMed Research International
39. The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
    Suzanne Ostrand‐Rosenberg, Lucas A. Horn, Samuel T. Haile · 2014 · The Journal of Immunology
40. ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis
    Hong Liu, Xinwei Kuang, Yongchang Zhang, Youqiong Ye, Jialu Li, Long Liang, Zuozhong Xie, Liang Weng, Jia Guo, Hui Li et al. · 2020 · Cancer Cell
41. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G
    Edgardo Delfino Carosella, Guillaume Ploussard, Joël LeMaoult, François Desgrandchamps · 2015 · European Urology
42. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
    Robert D. Leone, Ying-Chun Lo, Jonathan D. Powell · 2015 · Computational and Structural Biotechnology Journal
43. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice
    Luís Felipe Campesato, Romualdo Barroso‐Sousa, Leandro Jimenez, Bruna Corrêa, Jorge Sabbaga, Paulo M. Hoff, Luiz F. L. Reis, Pedro A. F. Galante, Anamaria A. Camargo · 2015 · Oncotarget
44. Pembrolizumab
    Leila Khoja, Marcus Otho Butler, Soonmo Peter Kang, Scot Ebbinghaus, Anthony Michael Joshua · 2015 · Journal for ImmunoTherapy of Cancer
45. Genomic and Epigenomic Alterations in Cancer
    Balabhadrapatruni V. S. K. Chakravarthi, Saroj Nepal, Sooryanarayana Varambally · 2016 · American Journal Of Pathology
46. The third group of the B7‐ CD 28 immune checkpoint family: HHLA 2, TMIGD 2, B7x, and B7‐H3
    Murali Janakiram, Urvi Ashok Shah, Weifeng Liu, Aimin Zhao, Mark Schoenberg, Xingxing Zang · 2017 · Immunological Reviews
47. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
    Cynthia L. Gay, Ronald J. Bosch, Justin Ritz, Jason M. Hataye, Evgenia Aga, Randall L. Tressler, Stephen W. Mason, Carey K. Hwang, Dennis M. Grasela, Neelanjana Ray et al. · 2017 · The Journal of Infectious Diseases
48. CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
    Margaret K. Callahan, Michael A. Postow, Jedd D. Wolchok · 2015 · Frontiers in Oncology
49. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
    Allison Ackerman, Oliver Klein, David F. McDermott, Wei Wang, Nageatte Ibrahim, Donald P. Lawrence, Anasuya Gunturi, Keith T. Flaherty, Frank Stephen Hodi, Richard F. Kefford et al. · 2014 · Cancer
50. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia
    Davide Brusa, Sara Serra, Marta Coscia, Davide Rossi, Giovanni Francesco D'Arena, Luca Laurenti, Ozren Jakšić, Giorgio Fedele, Giorgio Inghirami, Gianluca Gaïdano et al. · 2013 · Haematologica
51. Cancer immunotherapy targeting neoantigens
    Yong‐Chen Lu, Paul F. Robbins · 2015 · Seminars in Immunology
52. TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence
    2017
53. Molecular pathways and therapeutic targets in lung cancer
    Shtivelman, Emma, Hensing, Thomas, Simon, George R., Dennis, Phillip A., Otterson, Gregory A., Bueno, Raphael, Salgia, Ravi · 2014 · Oncotarget
54. Mitigating the toxic effects of anticancer immunotherapy
    Tara C. Gangadhar, Robert H. Vonderheide · 2014 · Nature Reviews Clinical Oncology
55. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy
    Man Li, Mengmeng Li, Yiliang Yang, Yingke Liu, Hanbing Xie, Qianwen Yu, Lifeng Tian, Xian Tang, Kebai Ren, Jianping Li et al. · 2020 · Journal of Controlled Release
56. Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study
    Yanbin Chen, Chuanyong Mu, Jian‐An Huang · 2012 · Tumori Journal
57. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
    Boyiadzis, Michael M., Kirkwood, John M., Marshall, John L., Pritchard, Colin C., Azad, Nilofer S., Gulley, James L. · 2018 · Journal for ImmunoTherapy of Cancer
58. PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction
    Kaoru Abiko, Masaki Mandai, Junzo Hamanishi, Yumiko Yoshioka, Noriomi Matsumura, Tsukasa Baba, Ken D Yamaguchi, Ryusuke Murakami, Ayaka Yamamoto, Budiman Kharma et al. · 2013 · Clinical Cancer Research
59. Recent Clinical Advances in Lung Cancer Management
    David H. Johnson, Joan H. Schiller, Paul A. Bunn · 2014 · Journal of Clinical Oncology
60. Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review
    Mamta Joshi, Ben Whitelaw, M.T.P. Palomar, Yin Wu, Paul Carroll · 2016 · Clinical Endocrinology
61. CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1
    Yunqin Lee, June Ho Shin, Michelle R. Longmire, Hua Wang, Holbrook E K Kohrt, Howard Y. Chang, John B. Sunwoo · 2016 · Clinical Cancer Research
62. Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer
    Emma Eriksson, Jessica Wenthe, Sandra Irenaeus, Angelica Loskog, Gustav Jörgen Ullenhag · 2016 · Journal of Translational Medicine
63. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy
    David R. Wilson, Rupashree Sen, J. Sunshine, D. Pardoll, J. Green, Y. Kim · 2017 · Nanomedicine: Nanotechnology, Biology and Medicine
64. Mechanisms of immune evasion in bladder cancer
    Paul L. Crispen, Sergei A. Kusmartsev · 2019 · Cancer Immunology Immunotherapy
65. Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells
    Michael Friberg Bruun Nielsen, Michael Bau Mortensen, Sönke Detlefsen · 2016 · World Journal of Gastroenterology
66. PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
    Abul Kalam Azad, Su Yin Lim, Zenobia D’Costa, Keaton Ian Jones, Angela Diana, Owen James Sansom, Philipp Krüger, Stanley K. Liu, William Gillies McKenna, Omer Dushek et al. · 2016 · EMBO Molecular Medicine
67. Cutaneous adverse effects of the immune checkpoint inhibitors
    Lindsey K. Collins, M. Shane Chapman, Joi B. Carter, Faramarz H. Samie · 2016 · Current Problems in Cancer
68. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
    Brian J. Christmas, Christine Isabelle Rafie, Alexander C. Hopkins, Blake Scott, Hayley S. Ma, Kayla A. Cruz, Skylar Woolman, Todd D. Armstrong, Roisín M. Connolly, Nilo A. Azad et al. · 2018 · Cancer Immunology Research
69. Tumor microenvironment in ovarian cancer: function and therapeutic strategy
    Yang, Yanfei, Yang, Yang, Yang, Jing, Zhao, Xia, Wei, Xiawei · 2020 · Frontiers in Cell and Developmental Biology
70. ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells
    Julien Faget, Nathalie Bendriss‐Vermare, Michael Gobert, Isabelle Durand, Daniel Olive, Cathy Biota, Thomas Bachelot, Isabelle Treilleux, Sophie Goddard‐Léon, Emilie Lavergne et al. · 2012 · Cancer Research
71. Pathways and therapeutic targets in melanoma
    Emma Shtivelman, Michael A. Davies, Patrick Hwu, James Chih-Hsin Yang, Michal Lotem, Moshe Oren, Keith T. Flaherty, David E. Fisher · 2014 · Oncotarget
72. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy
    Yuanyuan Liu, Linan Qiao, Sipei Zhang, Guoyun Wan, Bowei Chen, Ping Zhou, Ning Zhang, Yinsong Wang · 2017 · Acta Biomaterialia
73. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models
    Weiqing Jing, Donna M. McAllister, Emily P. Vonderhaar, Katie A. Palen, Matthew John Riese, Jill A. Gershan, Bryon D. Johnson, Michael B. Dwinell · 2019 · Journal for ImmunoTherapy of Cancer
74. TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts
    Grauel, Angelo L., Nguyen, Beverly, Ruddy, David, Laszewski, Tyler, Schwartz, Stephanie, Chang, Jonathan, Chen, Julie, Piquet, Michelle, Pelletier, Marc, Yan, Zheng et al. · 2020 · Nature Communications
75. The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
    Huff, Wei X., Kwon, Jae Hyun, Henriquez, Mario, Fetcko, Kaleigh, Dey, Mahua · 2019 · International Journal of Molecular Sciences
76. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
    Francesco Sabbatino, Vincenzo Villani, Jennifer Holmes Yearley, Vikram Deshpande, Lei Cai, Ioannis T. Konstantinidis, Christina Moon, Sjoerd P. F. T. Nota, Yangyang Wang, Ahmad Al-Sukaini et al. · 2015 · Clinical Cancer Research
77. Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
    S. Cedrés, Santiago Ponce-Aix, Jon Zugazagoitia, Irene Sansano, Ana B. Enguita, Alejandro Navarro, Alex Martínez‐Martí, Pablo Martínez, Enriqueta Felip · 2015 · PLoS ONE
78. Checkpoint inhibitors in triple‐negative breast cancer (TNBC): Where to go from here
    Maryann J. Kwa, Sylvia Adams · 2018 · Cancer
79. Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities
    Roy Rabbie, Peter M. Ferguson, Christian Molina‐Aguilar, David J. Adams, Carla Daniela Robles‐Espinoza · 2018 · The Journal of Pathology
80. Checkpoint inhibitors in pancreatic cancer
    Andreas Henriksen, Anne Dyhl-Polk, Inna Markovna Chen, Dorte Lisbet Nielsen · 2019 · Cancer Treatment Reviews
81. Neoadjuvant Treatment in Pancreatic Cancer
    Atsushi Oba, Felix Ho, Quoc Riccardo Bao, Mohammed H. Al-Musawi, Richard David Schulick, Marco Del Chiaro · 2020 · Frontiers in Oncology
82. Current Status and Future Directions
    Fumito Ito, Alfred E. Chang · 2013
83. Dendritic cell-targeted vaccines — hope or hype?
    Wolfgang Kastenmüller, Kathrin Kastenmüller, Christian Kurts, Robert A. Seder · 2014 · Nature reviews. Immunology
84. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies
    Fabienne Venet, Anne‐Claire Lukaszewicz, Didier M. Payen, Richard S. Hotchkiss, Guillaume Monneret · 2013 · Current Opinion in Immunology
85. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
    Evan J. Lipson, Victor E. Velculescu, Theresa S. Pritchard, Mark Sausen, Drew M. Pardoll, Suzanne Louise Topalian, Luis Alberto Diaz · 2014 · Journal for ImmunoTherapy of Cancer
86. Cytokine-Induced Modulation of Colorectal Cancer
    Lukas Franz Mager, Marie-Hélène Wasmer, Tilman T. Rau, Philippe Krebs · 2016 · Frontiers in Oncology
87. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies
    Elena Gabriela Chiorean, Andrew L. Coveler · 2015 · Drug Design Development and Therapy
88. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy
    Ninh My La-Beck, Gary W. Jean, Cindy Huynh, Saeed K Alzghari, Devin B. Lowe · 2015 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
89. Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment
    Yasuko Tada, Yosuke Togashi, D. Kotani, T. Kuwata, Eichi Sato, A. Kawazoe, T. Doi, H. Wada, Hiroyoshi Nishikawa, K. Shitara · 2018 · Journal of Immunotherapy for Cancer
90. Second-generation inhibitors of Bruton tyrosine kinase
    Jingjing Wu, Christina Liu, Stella T. Tsui, Delong Liu · 2016 · Journal of Hematology & Oncology
91. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
    Beatriz Sánchez-Correa, Isabel Valhondo, Fakhri Hassouneh, Nelson López-Sejas, Alejandra Pera, Juan Bergua, María José Arcos, Helena Bañas, Ignacio Casas-Avilés, Esther Durán et al. · 2019 · Cancers
92. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint
    Lina Zhao, Ye Liu, Jingbo Zhang, Yan Liu, Qi Qi · 2019 · Cell Death and Disease
93. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy
    Cheng Sun, Haoyu Sun, Weihua Xiao, Cai Zhang, Zhigang Tian · 2015 · Acta Pharmacologica Sinica
94. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
    Yang Zhang, Lei Wang, Yuan Li, Yunjian Pan, Haichuan Hu, Hang Li, Xiaoyang Luo, Ting Ye, yihua sun, haiquan chen et al. · 2014 · OncoTargets and Therapy
95. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers
    Étienne Becht, Nicolás A. Giraldo, Claire Germain, Aurélien de Reyniès, Pierre Laurent‐Puig, Jessica Zucman‐Rossi, Marie‐Caroline Dieu‐Nosjean, Catherine Sautès‐Fridman, Wolf H. Fridman · 2016 · Advances in immunology
96. Melanoma subtypes demonstrate distinct PD-L1 expression profiles
    Genevieve J. Kaunitz, Tricia R. Cottrell, Mohammed T. Lilo, Valliammai Muthappan, Jessica Esandrio, Sneha Berry, Haiying Xu, Aleksandra Ogurtsova, Robert A. Anders, Alexander H. Fischer et al. · 2017 · Laboratory Investigation
97. Microsatellite instability in Gastric Cancer: Between lights and shadows
    Elisabetta Puliga, Simona Corso, Filippo Pietrantonio, Silvia Giordano · 2021 · Cancer Treatment Reviews
98. The Role of CXC Chemokine Receptors 1–4 on Immune Cells in the Tumor Microenvironment
    Katharina Helene Susek, Maria Karvouni, Evren Alici, Andreas Lundqvist · 2018 · Frontiers in Immunology
99. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice
    Helge Frebel, Veronika Nindl, Reto Andreas Schuepbach, Thomas Braunschweiler, Kirsten Richter, Johannes Vogel, Carsten Alexander Wagner, Dominique Loffing‐Cueni, Michael Odo Kurrer, Burkhard Ludewig et al. · 2012 · The Journal of Experimental Medicine
100. Current Perspectives in Cancer Immunotherapy
     Theodoulakis Christofi, Stavroula Baritaki, Luca Falzone, Massimo Libra, Apostolos Zaravinos · 2019 · Cancers